Navigation Links
Researchers identify new cell targets for preventing growth of breast and other tumors
Date:4/23/2008

CHAPEL HILL Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression.

This step the creation of new blood vessels enables tumors to grow out of control and ultimately spread cancer to other parts of the body.

Targeting blood vessel formation, or angiogenesis, promises to be less toxic than the standard chemotherapy approach that kills cancer cells and normal cells alike. The new tactic has been shown by others to be successful in the treatment of breast cancer and colon cancer with the drug bevacizumab (commercially known as Avastin), which inhibits an important player in angiogenesis, a protein called vascular endothelial growth factor (VEGF).

There is a large amount of data that shows if you block angiogenesis, you can block tumor growth, said Dr. Nancy Klauber-DeMore, associate professor of surgery in the UNC School of Medicine and senior author on the study. But VEGF is not responsible for all of angiogenesis. We wanted to identify more targets for this therapeutic approach.

The most exciting aspect of this study is that we now have a very large list of potential targets that we will continue to work on for at least the next decade, Klauber-DeMore said.

A report of the study appeared online this month in the American Journal of Pathology. It will be published in the May 2008 print edition of the journal.

Angiogenesis only occurs normally in a few instances, such as wound healing, female reproduction and fetal development. But it also plays an important role in the growth and spread of cancer. New blood vessels provide essential nourishment to cancer cells, allowing them to grow, travel to other parts of the body and form new cancers.

Because tumors cannot grow or spread without the formation of new blood vessels, Klauber-DeMore sought new targets that are produced in excess (overexpressed) on tumor blood vessels. The hope is that by identifying proteins on these vessels, new drugs may be developed that block these proteins and put a stop to tumor blood vessel growth.

In a technique that took three years to perfect, the UNC researchers microdissected individual vascular cells from frozen sections of five cancerous and five normal breast tissue samples. They scanned the activity of thousands of genes in the isolated cells and then compared the gene activity between the tumor and normal vascular samples. They found 1,176 genes that differed in activity or expression between the two cell populations. Of these, 55 genes were overexpressed more than four-fold in blood vessels from breast cancer.

Because proteins that either lie on the cell surface or are secreted from the cell are the easiest targets for drug development, the researchers searched a database to pinpoint the likely cellular location of the proteins encoded by the candidate genes. They found that seven of the genes encoded membrane or secreted proteins. Four of these namely FAP, SFRP2, JAK3 and SMPD3 had not just increased gene expression, but also increased protein expression in breast tumor vessels, and thus could be good targets for the development of novel cancer therapies.

The researchers need to do further research to accurately define whether these proteins induce angiogenesis, Klauber-DeMore said. They can then design new compounds and test existing ones to see if they inhibit tumor growth.

Weve only looked at seven out of a list of 55 potential targets, Klauber-DeMore said. This work points us in the direction we need to go to develop the next generation of angiogenesis inhibitors.

Klauber-DeMore said that other researchers, led by George Coukos at Fox Chase Cancer Center, are trying the same approach with ovarian cancer, suggesting that this strategy may be applicable to many different tumor types.


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-5905
University of North Carolina at Chapel Hill
Source:Eurekalert

Related medicine news :

1. Melanoma lurks in larger skin lesions, NYU researchers find
2. Reduced Funds for Cancer is Cost of Iraq, Say Ex-White House Aide, Cancer Researchers
3. MU researchers reveal communication tactics used by sexual predators to entrap children
4. Penn researchers find potential in yeast for selecting Lou Gehrigs disease drugs
5. MU researchers find clue to cataract formation
6. Researchers evaluating food allergy treatment
7. U of M researchers identify process that may help treat Parkinsons, spinal cord injuries
8. OHSU Cancer Institute researchers discover key gene involvement in cancer development
9. Combining liver cancer treatments doubles survival rates, UVA researchers find
10. Leading HIV researchers to collaborate on vaccine development
11. Georgetown researchers find stem cell marker controls 2 key cancer pathways
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology: